Welcome to Markets Desk, your midday read on what's moving and why.
Equities are pushing higher this session, with the S&P five hundred up more than half a percent and the Dow leading the charge, gaining nearly a full point. The catalyst is diplomatic — reports of progress toward a near-term United States-Iran agreement are pulling crude lower and lifting risk appetite across the board, giving traders a reason to buy into the afternoon.
Shifting to the weight-loss drug space, Pfizer released new data today that sent a ripple through GLP-one territory. Eli Lilly and Novo Nordisk investors are watching closely, because if Pfizer's oral platform can deliver competitive efficacy, the duopoly these two have enjoyed in the obesity market faces a genuine structural challenge — and that repricing risk is real.
And in the corner of the market that never quite settles down, SpaceX and Tesla merger chatter is intensifying again. The two companies have been sharing employees, intellectual property, and capital for some time now, and with xAI increasingly in the picture, the question of whether Elon Musk consolidates these assets under one roof is no longer purely hypothetical — it's a valuation story worth watching.
That's the tape. Markets Desk, signing off the floor.
